The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.
Related to this article
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
The FDA approved a prefilled pen for the administration of ropeginterferon alfa-2b-njft in adult patients with polycythemia vera.
Advertisement
Advertisement
Trending on OncLive
1
Dr Geyer on the FDA Approval of Post-Neoadjuvant T-DXd for HER2+ Breast Cancer
2
Dr Vachhani on Phase 2 Efficacy/Safety Data for Sapablursen in Polycythemia Vera
3
FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD
4
FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification
5